Skip to content
medical devices and technologies hero image
medical devices and technologies hero image

Medical Devices and Technologies

Our global medical devices and technologies group acts for companies and institutions across the sector and provides advice to ensure that clients are well placed to manage the challenges they face to capitalise on opportunities

Our global medical devices and technologies group acts for companies and institutions across the sector and provides advice to ensure that clients are well placed to manage the challenges they face to capitalise on opportunities.

Our team spans disciplines including intellectual property (contentious and non-contentious), regulatory, product liability, mergers and acquisitions, commercial transactions (including licensing and collaborations), and capital markets and finance matters.

Our international network ensures that we have a ready resource of expertise in a wide range of jurisdictions and that we are well positioned to advise on cross-border work. Our lawyers have been advising clients in the sector for many years and have developed a deep understanding of the issues affecting the industry. This ensures that we add value to any matter and there is no learning curve.

For example, our team has been closely following the current proposed changes to the European medical devices regulatory framework. We have also been tracking and advising our clients on regulatory issues in the context of emerging technologies such as device/drug combinations, medical apps and other “connected health” initiatives. In these areas we use our broad and interdisciplinary experience to help our clients navigate what may often be rapidly evolving or uncertain regulatory pathways and manage the risks of new product development.

Our clients in the medical devices sector include Biomet, Samsung, GE Healthcare, Johnson & Johnson, Fresenius, Covidien, St Jude Medical and Novartis.

News & insights

Image of a skyscraper with blue tinted windows

News: 08 JULY 2021

M&A deal values soar as transactions recover globally in H1 2021

Allen & Overy’s latest M&A Insights report* reveals a remarkable global recovery in M&A transactions during the first half of 2021. Deal values were up by 131% on the same period in 2020, while deal…

Read more
close up of glaze building

Publications: 08 JULY 2021

Innovation and search for growth spark MedTech rebound

The postponement of non-urgent medical procedures in the early days of the Covid-19 pandemic led to a lull in MedTech transaction activity in the first half of 2020 but makers of medical devices…

Read more

Blog Post: 13 JANUARY 2020

Germany: Reimbursement of Digital Health Apps – A “World First”

The Digital Healthcare Act (Digitale-Versorgung-Gesetz DVG) was published in the German Federal Law Gazette (Bundesgesetzblatt) on 18 December 2019 and entered into force on 19 December 2019, having…

Read more

Blog Post: 03 JANUARY 2020

Life Sciences and healthcare growth in more challenging times

At a time of heightened regulatory and market uncertainty, it’s perhaps surprising to see life sciences and healthcare sector M&A continuing to grow so strongly. Indeed, with deal value up by more…

Read more

Download our sector brochure

Life sciences A&O red molecules

An insight in to our Life Science and Healthcare sector 2021

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.